Letter to the editor: Epidemiology of the SARS-CoV-2 variant Omicron BA.2 – vigilance needed

References

1. Fonager J, Bennedbæk M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, et al. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Euro Surveill. 2022;27(10)2200181.  https://doi.org/10.2807/1560-7917.ES.2022.27.10.2200181  PMID: 35272746 
2. Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, et al. Virological characteristics of SARS-CoV-2 BA.2 variant. bioRxiv. 2022:2022.02.14.480335. Preprint.  https://doi.org/10.1101/2022.02.14.480335 
3. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med.2022;386(10):995-8.  https://doi.org/10.1056/NEJMc2119407  PMID: 35263535 
4. Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022. . Epub ahead of print. https://doi.org/10.1038/s41586-022-04594-4  PMID: 35240676 
5. Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant. Res Sq.2022:23:rs.3.rs-1362445. Preprint.
6. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish households. medRxiv. 2022:2022.01.28.22270044. Preprint.  https://doi.org/10.1101/2022.01.28.22270044 
7. Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med. 2022. . Epub ahead of print. https://doi.org/10.1056/NEJMc2201849  PMID: 35294809